Imported Medicines in Hainan Lecheng: What to Confirm First
A medicine approved overseas is not automatically available to you in Hainan Lecheng, China. The official import-use framework depends on the product, designated medical institution and relevant approvals. This guide, checked on 10 October 2026, explains what to confirm with the hospital before arranging travel, including informed consent, pre-review and any proposed use after leaving the institution.
Which products does the 2023 framework describe?
Article 2 of Hainan’s 2023 management provisions defines clinically needed imported medicines as overseas-approved products that lack Chinese registration and cannot be replaced by products already marketed domestically; vaccines are excluded. Its device definition covers overseas-approved devices for which no same-kind product is registered in China. The products are for a specific medical purpose at the designated institution applying to use them.
Confirm the institution and informed-consent process
Under Articles 4 and 9, the designated institution bears primary responsibility for use-safety risks and applies after assessing the product’s advanced nature, effectiveness and controllable risks. Article 18 requires the institution to explain the clinically needed import approval, the absence of a domestic substitute or the treatment plan, and sign informed-consent documents with the patient or family before use.
Pre-review still requires an import-use application
The March 2026 measures describe pre-review as an advance regulatory service before a designated institution finishes its internal introduction process or the institution using the product is finally determined. Article 13 still requires a medical institution to apply for import and use under the relevant provisions and application guide. A pre-reviewed listing therefore does not itself confirm an individual treatment appointment.
Ask about take-away use and follow-up
Article 19 of the 2023 provisions allows take-away use only after the institution fully assesses the patient’s needs and product characteristics and establishes safety and effectiveness: the product must be for personal use, in a reasonable quantity and with controllable risk. The July 2025 notice says the institution sets the frequency and method of photo/video traceability uploads using patient credit assessment, adverse reactions and diversion risks, and records these in the take-away filing. It must continue monitoring safe use.
- Which named medicine or device and indication are being considered?
- Which designated institution is applying, and what approvals are still needed?
- Who will explain alternatives, the treatment plan and consent documents?
- If take-away use is proposed, what quantity, monitoring and follow-up apply?
Frequently asked questions
Is overseas approval enough to arrange treatment?
Does pre-review replace the import-use application?
Can I assume I may take the medicine away?
This article was produced with AI assistance and reviewed against Uwell Cloud editorial and compliance standards.